Zobrazeno 141 - 150
of 211
pro vyhledávání: ''
Autor:
Chintan Y. Shah, Maulik R. Patel, Rahul J. Gupta, Raghav Sukhadiya, Deven Parmar, Heather Heading, Mukul R. Jain, Devang P. Parikh, Kinjal Barot, Harilal Patel, Hardik B. Patel, Nuggehally R. Srinivas, Vyom N. Dholakia, Kevinkumar Kansagra, Rajendrakumar H. Jani, Krupi Parmar, Jason Lickliter
Publikováno v:
Clinical Pharmacokinetics
This phase I study of ZYAN1 was conducted to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. The study was a randomized, double-blind, placebo-controlled phase I study carried out in two pa
Autor:
Arnold B. Sterman, Frank R. Ernst, Jennifer Welstead, Riad Elmor, Walter Sandulli, MaryKate Lavan
Publikováno v:
Drugs in R&D
Introduction Medication changes involving levothyroxine—either dose titrations or switching formulations—occur frequently in patients with erratic thyroid-stimulating hormone (TSH) levels and persistent hypothyroid symptoms. We investigated wheth
Autor:
Rodrigo Pereira Duquia, André Vicente Esteves de Carvalho, Bernardo L. Horta, Renan Rangel Bonamigo
Publikováno v:
Drugs in R&D
Background Psoriasis is an immune-mediated inflammatory disease for which treatment has evolved over the past few years due to the introduction of immunobiologic and small molecule inhibitor medications. A better understanding of the comparative effi
Autor:
Anthony Barron, Tim Wilsdon
Publikováno v:
Pharmaceutical Medicine
Although significant progress has been made in the past decade in the treatment of both common and rare cancers, there has been significant concerns about the cost, and especially the value, of certain new oncology drugs. These concerns touch upon a
Autor:
Eric Zijlstra, Tim Heise, Jacob Bonde Jacobsen, Hanne Haahr, Kirstine Stender-Petersen, Ulrike Hövelmann, Leszek Nosek
Publikováno v:
Clinical Pharmacokinetics
Background Absorption of current rapid-acting insulins is too slow for patients with diabetes mellitus to achieve optimal postprandial glucose control. Faster-acting insulin aspart (faster aspart) is insulin aspart in a new formulation with faster ea
Publikováno v:
Pharmacoeconomics
Background There are an increasing number of studies using simulation models to conduct cost-effectiveness analyses for type 2 diabetes mellitus. Objective To evaluate the relationship between improvements in glycosylated haemoglobin (HbA1c) and simu
Publikováno v:
International Journal of Clinical Pharmacy
Background Overactive bladder syndrome is a condition where one or more of the symptoms such as pollakiuria, urgent need to urinate, nocturia and urinary incontinence is observed. Its prevalence ranges between 7 and 27 % in men and 9–43 % in women.
Publikováno v:
Drugs in R&D
Des-aspartate-angiotensin I (DAA-I) is an endogenous angiotensin peptide and a prototype angiotensin receptor agonist (ARA). It acts on the angiotensin AT1 receptor and antagonises the deleterious actions of angiotensin II. DAA-I attenuates animal mo
Autor:
John N. Feder, H. David Inzunza, Diana M. Cardona, John Cogswell, James Novotny, Gabe Mintier, Qiuyan Wu
Publikováno v:
Molecular Diagnosis & Therapy
Aim Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non–small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in
Autor:
Haley E. Melikian, Rita R. Fagan, Andrew R. Tapper, Iris V. Rivera, Jun Xie, Nicholas C Bolden, Patrick J. Kearney, Jenya Kolpakova, Guangping Gao, Gilles E. Martin, Rubing Zhao-Shea, Carolyn G. Sweeney, Lindsey A. Smith
Publikováno v:
Neuropsychopharmacology
Dopamine (DA) signaling is critical for movement, motivation, and addictive behavior. The neuronal GTPase, Rit2, is enriched in DA neurons (DANs), binds directly to the DA transporter (DAT), and is implicated in several DA-related neuropsychiatric di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021ff3a3553e1030be4920062c655cf7
https://europepmc.org/articles/PMC6901441/
https://europepmc.org/articles/PMC6901441/